Biodexa shares surge 50.79% after-hours as first European patients enrolled in pivotal Phase 3 Serenta trial, targeting $7B FAP market.

Biodexa Pharmaceuticals (BDRX) surged 50.79% in after-hours trading following the announcement that it enrolled the first European patients into its pivotal Phase 3 Serenta trial for fibrous adenomas (FAP). This milestone, reported by GlobeNewswire four days prior, marked progress in the drug’s regulatory pathway, supported by earlier news of the trial’s CTA approval in Europe and activation of the first European site. The enrollment underscores the company’s advancement toward addressing a $7 billion market, fueling investor optimism about the therapy’s commercial potential.